Brief Overview:

Perampanel (Fycompa®) recently became available in the United States. As it is a new drug and has not been thoroughly tested in children, or infants, we cannot support its use for the treatment of infantile spasms. However, based on perampanel's mechanism of action, there has been some optimism that it may be effective. Nevertheless, effectiveness and safety have not yet been established. It is certainly not recommended as a first-line therapy for infantile spasms. This medication is supplied as a tablet (which can be crushed).


A ideal dosage for treatment of infantile spasms is not known. 

Side Effects:

In clinical trials with adult patients, perampanel occasionally caused sedation, fatigue, dizziness, and clumsiness, but was generally well tolerated. As this is a new drug, the long-term safety has not been conclusively established. 


This medication should be administered only under the direct supervision of a physician.

Although efforts are made to keep this website correct and up-to-date, we urge caution in interpreting the information you find here. This is in no way a substitute for the advice and care of a pediatric neurologist. Please view the terms of use.

English | Español